Free tool
FAERS Monitor: Aggrastat
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020912 or its brand name (Aggrastat, Tirofiban Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
2,780
Serious
2,466
89% of reports
Hospitalization
401
Death reported
442
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- haemorrhage376
- thrombocytopenia295
- myocardial infarction206
- angina pectoris187
- haemorrhage intracranial179
- death146
- cardiac failure acute118
- cerebral haemorrhage110
- acute respiratory failure99
- cardiac failure88
- vascular stent thrombosis80
- infarction53
- drug ineffective48
- cardiogenic shock45
- acute myocardial infarction44
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 45 |
| 2005 | 169 |
| 2006 | 134 |
| 2007 | 59 |
| 2008 | 19 |
| 2009 | 7 |
| 2010 | 10 |
| 2011 | 11 |
| 2012 | 31 |
| 2013 | 15 |
| 2014 | 12 |
| 2015 | 14 |
| 2016 | 44 |
| 2017 | 74 |
| 2018 | 98 |
| 2019 | 1,159 |
| 2020 | 236 |
| 2021 | 137 |
| 2022 | 305 |
| 2023 | 23 |
| 2024 | 66 |
| 2025 | 29 |
| 2026 | 83 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,379 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| vascular stent thrombosisSignal | 80 | 309.6 | 248.3 | 23,345 |
| cardiac failure acuteSignal | 118 | 136.4 | 114.2 | 15,454 |
| haemorrhage intracranialSignal | 179 | 91.7 | 79.5 | 15,782 |
| infarctionSignal | 53 | 59.0 | 45.2 | 2,945 |
| angina pectorisSignal | 187 | 49.7 | 43.2 | 8,827 |
| acute respiratory failureSignal | 99 | 39.1 | 32.2 | 3,625 |
| haemorrhageSignal | 376 | 27.3 | 24.9 | 9,517 |
| cardiogenic shockSignal | 45 | 23.8 | 17.8 | 958 |
| cerebral haemorrhageSignal | 110 | 23.3 | 19.4 | 2,324 |
| thrombocytopeniaSignal | 295 | 20.0 | 18.0 | 5,323 |
| acute myocardial infarctionSignal | 44 | 11.3 | 8.4 | 403 |
| myocardial infarctionSignal | 206 | 8.9 | 7.8 | 1,456 |
| cardiac failureSignal | 88 | 8.3 | 6.8 | 559 |
| death | 146 | 1.3 | 1.1 | 9 |
| drug ineffective | 48 | 0.3 | 0.2 | 97 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.